A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 8, 2017

Primary Completion Date

November 15, 2019

Study Completion Date

November 15, 2019

Conditions
Sarcoidosis, Pulmonary
Interventions
DRUG

Glucocorticoid (prednisone or prednisolone)

≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy

Trial Locations (20)

5602

Catharina Ziekenhuis, Eindhoven

15213

University of Pittsburgh Medical Center, Pittsburgh

21287

Johns Hopkins University School of Medicine - Baltimore, Baltimore

28401

PMG Research of Wilmington, LLC, Wilmington

29425

Medical University of South Carolina, Charleston

35233

University of Alabama Birmingham, Birmingham

44195

Cleveland Clinic - Taussig Cancer Institute, Cleveland

45267

University of Cincinnati Medical Center, Cincinnati

52242

University of Iowa, Iowa City

63110

Pulmonary and Critical Care Medicine-Washington University School of Medicine, St Louis

98405

MultiCare Institute for Research and Innovation, Tacoma

3015 CE

Erasmus University Medical Center, Rotterdam

7207 AE

Onderzoekscentrum longziekten Zutphen, Zutphen

NW1 2BU

University College London Hospitals NHS Foundation Trust - University College Hospital, London

SE1 1YR

Richmond Pharmacology, London

W12 0NN

Imperial College London - Hammersmith Hospital Campus, London

M23 9LT

University Hospital of South Manchester NHS Foundation Trust -Wythenshawe Hospital - North West Lung, Manchester

0X3 7LE

Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford

BS10 5NB

Southmead Hospital, Westbury-on-Trym/ Bristol

WV10 0QP

The Royal Wolverhampton Hospitals NHS Trust - Newcross Hospital, Wolverhampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY